Compare Robinhood Markets, Inc. (HOOD) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Robinhood Markets, Inc. vs Sana Biotechnology Inc — how do they compare? Robinhood Markets, Inc. trades at $109.1 (market cap $96.21B), while Sana Biotechnology Inc trades at $2.8 (market cap $836.71M). The key difference: Robinhood Markets, Inc. is far larger — about 115× Sana Biotechnology Inc's market cap, and Robinhood Markets, Inc. is trading nearer its 52-week high, Sana Biotechnology Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Robinhood Markets, Inc. for 75 Days and Sana Biotechnology Inc for 23 Days on average.
| HOOD | SANA | |
|---|---|---|
Market Cap | $96.21B | $836.71M |
Volume | 22,572,153 | 4,507,444 |
Sector | Financials | Health |
52-Week High | $152.46 | $5.92 |
52-Week Low | $65.16 | $2.68 |
Typical Hold Time | 75 Days | 23 Days |
Enterprise Value | $102.75B | $749.96M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Robinhood (HOOD) trades at $109.02, down 0.45% on the day, with a bullish technical signal and strong support at $105. The company reported robust 2025 results with revenue of $4.47B and net income of $1.88B, though valuation ratios like a P/E of 47.35 remain elevated. Recent news highlights expansion into 24/7 stock trading and new product launches aimed at driving growth.
The outlook is positive with a consensus price target of $137.53, implying 26% upside, supported by analyst optimism and product innovation. Key risks include high valuation sensitivity, competitive pressures, and regulatory scrutiny over new offerings like leveraged crypto trading, which could impact investor sentiment and stock performance.
SANA Biotechnology trades at $2.84, up 4.41% today, while showing bearish technical signals with moving averages indicating selling pressure. The company remains pre-revenue with significant losses (-$244.17M net income in 2025) and negative cash flow from operations. Recent investor conference presentations highlight ongoing development of engineered cell therapies, though earnings have missed expectations in two of the last three quarters.
Despite analyst optimism (82% buy ratings), SANA faces substantial execution risk as a clinical-stage biotech with no current revenue and high cash burn. The stock's outlook depends heavily on clinical trial progress and future funding needs, with current valuation at 5.41x book value despite negative profitability metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Robinhood Markets, Inc.
Robinhood Markets, Inc. operates a financial services platform. The Company offers brokerage and cash management applications such as stocks, exchange-traded funds, options, and cryptocurrency. Robinhood Markets serves clients in the United States.
Read more on HOOD →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
